Privia Health Group, Inc. (PRVA) Stock Analysis: A Promising 39.57% Upside Potential
Privia Health Group, Inc. (PRVA) is drawing investor attention with a potential 39.57% upside, based on an average analyst target price of $31.25 against its current trading price of $22.39. The company, a leader in health information services, shows strong revenue growth of 32.50% and positive analyst sentiment, with 19 buy ratings. Despite short-term bearish technical indicators, its innovative value-based care models position it favorably for future growth in the healthcare sector.
Public Sector Pension Investment Board Increases Position in Privia Health Group, Inc. $PRVA
The Public Sector Pension Investment Board significantly increased its stake in Privia Health Group, Inc. by 25.9% in Q3, now holding 450,010 shares valued at approximately $11.2 million. This move is part of a broader trend of institutional accumulation in Privia Health, with overall institutional ownership reaching about 94.48%. Despite recent insider sales, analysts rate the stock a "Moderate Buy" with a target price of $30.50.
Understanding the Setup: (PRVA) and Scalable Risk
This article provides an analysis of Privia Health Group Inc. (NASDAQ: PRVA), highlighting a neutral near-term sentiment that could precede mid-term weakness. It identifies a mid-channel oscillation pattern and an exceptional 30.9:1 risk-reward short setup. The piece also details various AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging.
Privia Health Group, Inc. (NASDAQ:PRVA) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Privia Health Group, Inc. (NASDAQ:PRVA) has received a consensus "Moderate Buy" rating from sixteen brokerages, with an average 12-month price target of $30.50. Despite this positive outlook and recent price target increases from firms like Canaccord Genuity and JPMorgan, senior insiders recently sold significant shares, with Director Matthew Shawn Morris and CFO David Mountcastle reducing their holdings by 16.68% and 12.14% respectively. Institutional investors hold a substantial 94.48% of the company, which currently trades at a high P/E ratio of 166.17, indicating an elevated valuation.
Principal Financial Group Inc. Sells 60,425 Shares of Privia Health Group, Inc. $PRVA
Principal Financial Group Inc. reduced its stake in Privia Health Group, Inc. by selling 60,425 shares, now holding 2,744,213 shares valued at approximately $68.33 million. This comes as Privia Health Group surpassed earnings expectations in its latest quarter with significant revenue growth. Analysts maintain a generally positive outlook on the stock, with an average target price of $30.50 compared to its current trading price of around $22.44.
The Technical Signals Behind (PRVA) That Institutions Follow
This article provides an in-depth technical analysis of Privia Health Group Inc. (NASDAQ: PRVA), highlighting institutional trading strategies derived from AI models. It identifies a weak near-term sentiment but an exceptional risk-reward setup targeting a 10.0% gain. The piece outlines specific position trading, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis for PRVA.
Van Berkom & Associates Inc. Has $93.99 Million Position in Privia Health Group, Inc. $PRVA
Van Berkom & Associates Inc. has significantly increased its stake in Privia Health Group, Inc. (NASDAQ:PRVA) by 30.1%, now holding 3,774,565 shares valued at $93.99 million, making it their 8th largest position. Research analysts maintain a "Moderate Buy" consensus with an average price target of $30.50, despite recent insider share sales. Privia Health Group exceeded quarterly earnings and revenue estimates, though its stock currently trades at $22.44.
Privia Health Group, Inc. (PRVA) Stock Analysis: A 33.49% Potential Upside Amid Strong Buy Ratings
Privia Health Group, Inc. (PRVA) is positioned for a potential upside of 33.49%, with analysts setting an average target price of $31.25 and a strong consensus of 19 buy ratings. The company, which operates in health information services, shows impressive revenue growth of 32.50% and a positive EPS of 0.14, indicating effective equity leverage. Despite not offering dividends, its substantial free cash flow of over $103 million suggests reinvestment into growth, making PRVA a compelling opportunity for investors in the healthcare sector.
Privia Health’s Upcoming Earnings: A Test for Its Value-Based Care Model
Privia Health Group, Inc. is set to release its Q4 and full-year 2025 financial results on February 26, 2026, which will be a key indicator of its strategic expansions and value-based care model. Investors will focus on network growth, operational efficiency in value-based care contracts, and evidence of increasing profitability. The company's future guidance for fiscal year 2026, to be provided during the analyst conference call, will be crucial in shaping investor sentiment regarding its growth trajectory.
Privia Health’s Upcoming Earnings: A Test for Its Value-Based Care Model
Privia Health Group, Inc. is preparing to release its fourth-quarter and full-year 2025 financial results on February 26, 2026. Investors will be closely watching to see if the company's strategic expansions are yielding financial progress and if its value-based care model is proving resilient. The market will also scrutinize management's forward-looking guidance for 2026, with an emphasis on network growth, operational efficiency, and profitability signals.
Privia Health Group, Inc. (PRVA): A Bull Case Theory
This article summarizes a bullish thesis on Privia Health Group, Inc. (PRVA), a technology-enabled platform assisting medical groups with value-based care. The thesis highlights PRVA's asset-light model, strong financials, and potential for significant growth and upside, positioning it as a leader in value-based care or an acquisition target. The company demonstrates superior performance in its sector, with management targeting about 20% annual organic EBITDA growth.
180,183 Shares in Privia Health Group, Inc. $PRVA Acquired by Great Lakes Advisors LLC
Great Lakes Advisors LLC has acquired a new position of 180,183 shares in Privia Health Group, Inc. (NASDAQ:PRVA) during the third quarter, valued at approximately $4.49 million, representing about 0.15% ownership. This acquisition follows Privia Health Group's strong Q3 performance, where it exceeded earnings estimates with $0.29 EPS against an expected $0.06 and reported a 32.5% increase in revenue year-over-year. Despite significant institutional ownership and a "Moderate Buy" consensus rating from analysts, some company insiders have recently sold shares.
A Look At Privia Health Group (PRVA) Valuation After Sector Pressures From UnitedHealth Guidance Update
Privia Health Group (PRVA) experienced a share price decline following UnitedHealth Group's lowered revenue expectations and flat Medicare Advantage payment rates, impacting healthcare provider stocks across the sector. Despite recent pressures, with PRVA trading at US$23.22, analysts suggest a significant intrinsic discount of about 42% and a 35% discount to target prices, indicating a potential investment opportunity. The company's valuation is underpinned by its growth in value-based care and expanding margins from risk-sharing agreements, though future labor costs and market consolidation could pose risks.
Should UnitedHealth’s Medicare Outlook And Restructuring Require Action From Privia Health Group (PRVA) Investors?
UnitedHealth Group's cautious revenue outlook and restructuring, influenced by flat Medicare Advantage payment rates, have caused a sector-wide stir, impacting companies like Privia Health Group. Despite Privia Health's strong Accountable Care Organization (ACO) performance and increased EBITDA guidance, its stock experienced a 6.5% pullback due to sensitive market sentiment regarding Medicare Advantage payment headlines. Investors are advised to consider the policy-driven risks and their potential impact on Privia Health's investment narrative, especially as reimbursement and policy risks become more prominent factors to watch.
Should UnitedHealth’s Medicare Outlook And Restructuring Require Action From Privia Health Group (PRVA) Investors?
UnitedHealth Group's cautious revenue outlook and restructuring plans, coupled with flat Medicare Advantage payment rates, have raised sector-wide concerns, impacting companies like Privia Health Group. Despite Privia Health's strong Accountable Care Organization performance and increased 2025 Adjusted EBITDA guidance, the broader market sentiment due to UnitedHealth's news has led to a 6.5% pullback in Privia's stock. This highlights the sensitivity of the healthcare investment landscape to Medicare Advantage payment headlines and policy risks.
Kornitzer Capital Management Inc. KS Sells 93,490 Shares of Privia Health Group, Inc. $PRVA
Kornitzer Capital Management Inc. KS has reduced its stake in Privia Health Group, Inc. (NASDAQ:PRVA) by 42.9%, selling 93,490 shares and retaining 124,535 shares valued at approximately $3.10 million. Additionally, company insiders, including CFO David Mountcastle and director Matthew Shawn Morris, sold significant amounts of shares. Despite these sales, analysts remain largely bullish on PRVA, with a consensus "Moderate Buy" rating and a target price of $30.50, following the company's recent strong revenue and EPS beat.
Privia Health Group (NASDAQ:PRVA) Trading Down 6.3% - Should You Sell?
Privia Health Group (NASDAQ: PRVA) saw its shares fall by 6.3% on Tuesday, despite beating quarterly earnings and revenue estimates. Analysts maintain a "Moderate Buy" rating with an average price target offering significant upside. However, the stock trades at a high P/E ratio, and recent insider selling activity has been noted.
Why Privia Health (PRVA) Shares Are Plunging Today
Privia Health (PRVA) shares fell 6.5% after UnitedHealth Group warned of lower revenue in 2026 due to restructuring efforts and elevated medical costs. This cautious outlook, combined with proposed flat Medicare Advantage payment rates, created concerns across the healthcare provider sector, impacting Privia Health. Despite today's drop, Privia Health's shares are not highly volatile, and the company had previously raised its Adjusted EBITDA guidance for 2025 following strong Medicare shared savings performance.
Why Privia Health (PRVA) Shares Are Plunging Today
Privia Health (PRVA) shares fell 6.5% after industry giant UnitedHealth Group warned of lower 2026 revenue due to restructuring and elevated medical costs, impacting the entire healthcare provider sector. This cautious outlook, combined with proposed flat Medicare Advantage payment rates, created a ripple effect, causing investors to sell off shares in related companies like Privia Health. Despite the current dip, the company had previously shown strong performance with its Accountable Care Organizations, achieving significant Medicare shared savings in 2024.
Precision Trading with Privia Health Group Inc. (PRVA) Risk Zones
This article provides a precision trading analysis for Privia Health Group Inc. (PRVA), highlighting a strong near-term sentiment with neutral mid and long-term outlooks. It details three trading strategies—Position, Momentum Breakout, and Risk Hedging—along with their respective entry, target, and stop-loss zones. The analysis emphasizes an exceptional 31.4:1 risk-reward setup targeting a 9.4% gain versus 0.3% risk.
Take Care Before Diving Into The Deep End On Privia Health Group, Inc. (NASDAQ:PRVA)
Privia Health Group, Inc. (NASDAQ:PRVA) currently has a price-to-sales (P/S) ratio of 1.4x, which is comparable to the healthcare industry median in the US. Despite recent significant revenue growth (19% last year, 61% over three years) and a forecast of 12% annual growth for the next three years (exceeding the industry average of 6%), the market's P/S valuation suggests some investor skepticism regarding the company's ability to sustain this growth or potential underlying risks. The article advises investors to look beyond the seemingly average P/S ratio and assess the company's balance sheet and other risk factors.
Privia Health to Report Fourth Quarter 2025 Results on Thursday, February 26
Privia Health Group, Inc. announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, before market open on Thursday, February 26, 2026. Management will host a conference call on the same day at 8:00 AM ET to discuss the results and future outlook. The press release and webcast details will be available on the company's Investor Relations website.
Take Care Before Diving Into The Deep End On Privia Health Group, Inc. (NASDAQ:PRVA)
Privia Health Group (NASDAQ: PRVA) currently has a price-to-sales (P/S) ratio of 1.4x, which is considered "middle-of-the-road" compared to the healthcare industry median of 1.3x in the US. Despite impressive revenue growth of 19% last year and an anticipated 12% annual growth over the next three years (outperforming the industry's 6.0%), its P/S ratio does not fully reflect this positive outlook. The market may be factoring in some underlying risks or anticipating potential revenue instability, preventing the P/S from aligning with its strong growth prospects.
Privia Health to Report Fourth Quarter 2025 Results on Thursday, February 26
Privia Health Group, Inc. (Nasdaq: PRVA) announced it will release its fourth-quarter and twelve-month 2025 financial results before market open on Thursday, February 26, 2026. The company will also host a conference call at 8:00 am ET on the same day to discuss the results and future outlook. Interested parties can access the press release and webcast details on Privia Health's Investor Relations website.
Privia Health to Report Fourth Quarter 2025 Results on Thursday, February 26
Privia Health Group, Inc. (Nasdaq: PRVA) announced it will release its fourth-quarter and twelve-month financial results for 2025 before market open on Thursday, February 26, 2026. A press release will be publicly disseminated by 7:00 am ET on their Investor Relations website, followed by a conference call at 8:00 am ET to discuss the results and future outlook. The company, a physician enablement firm, operates in 15 states and the District of Columbia.
Take Care Before Diving Into The Deep End On Privia Health Group, Inc. (NASDAQ:PRVA)
Privia Health Group (NASDAQ:PRVA) currently has a price-to-sales (P/S) ratio of 1.4x, which is considered average for the U.S. healthcare industry. Despite the company's strong revenue growth, outperforming industry averages, its P/S ratio does not reflect this positive outlook. This suggests investors may be concerned about potential risks or the sustainability of its future growth.
Privia Health to Report Fourth Quarter 2025 Results on Thursday, February 26
Privia Health Group, Inc. announced it will release its fourth-quarter and full-year 2025 financial results on Thursday, February 26, 2026, before market open. The company's management will host a conference call at 8:00 AM ET on the same day to discuss the results and future outlook. Interested parties can access the press release on Privia Health's Investor Relations website and listen to the conference call via live webcast or replay.
Privia Health Group, Inc.'s (NASDAQ:PRVA) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Privia Health Group (NASDAQ:PRVA) has seen its stock decline by 11% recently, but its underlying financial indicators suggest a strong potential for long-term growth. The company's Return on Equity (ROE) is 3.2%, which is lower than the industry average, yet it has achieved a significant net income growth of 52% over the last five years. This growth is attributed to the company reinvesting all its profits back into the business, indicating efficient management despite a low ROE.
Privia Health Group, Inc. (PRVA) Investor Outlook: Revenue Growth Sparks a 34% Upside Potential
Privia Health Group, Inc. (PRVA) is a healthcare technology firm showing strong growth with a 32.50% revenue increase and a potential 34.06% upside according to analyst forecasts. Despite its current trading price, the company's focus on physician enablement and effective operational strategies position it as an attractive opportunity for growth-oriented investors in the health information services industry. Investors are advised to conduct thorough due diligence given the growth-oriented valuation metrics.
Privia Health Group, Inc. (NASDAQ:PRVA) Receives Average Recommendation of "Moderate Buy" from Analysts
Privia Health Group, Inc. (NASDAQ:PRVA) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $30.50. The company recently surpassed Q3 earnings expectations, reporting an EPS of $0.29 against an estimated $0.06 and revenue of $580.4 million, beating the $495.0 million forecast. Insider sales by a director and CFO were noted, alongside strong institutional ownership of approximately 94.5% of the company's stock.
Privia Health Group Inc (PRVA) Trading 4.29% Higher on Jan 15
Privia Health Group Inc (PRVA) saw its shares surge by 4.29% on January 15, reaching an intraday high of $23.83. Analysts have an average one-year price target of $31.55 for PRVA, suggesting a potential upside of 32.40%, with a consensus "Outperform" recommendation. GuruFocus estimates a fair value of $49.51, indicating an even larger upside of 107.76%.
Technical Reactions to PRVA Trends in Macro Strategies
This article analyzes Privia Health Group Inc. (NASDAQ: PRVA) with a focus on technical reactions and macro strategies. It identifies weak near-term sentiment, a mid-channel oscillation pattern, and an exceptional short setup targeting a 9.1% downside with minimal risk. The report also outlines distinct AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging strategies.
Robeco Institutional Asset Management B.V. Acquires Shares of 51,756 Privia Health Group, Inc. $PRVA
Robeco Institutional Asset Management B.V. recently acquired 51,756 shares of Privia Health Group, Inc. (NASDAQ:PRVA) for approximately $1.29 million during the third quarter. Institutional investors now hold 94.48% of the company's stock, and analysts maintain a "Moderate Buy" rating with an average target price of $30.50. Despite some recent insider selling by executives, insiders still retain a significant 10.7% ownership in the company.
Privia Health Group (NASDAQ:PRVA) Raised to Moderate Buy at Royal Bank Of Canada
Royal Bank of Canada upgraded Privia Health Group (NASDAQ:PRVA) to a "Moderate Buy" rating, aligning with the MarketBeat consensus target of $30.50. Despite this, the stock trades at an expensive valuation with a high P/E of 177.24 and low net margin of 0.89%. Insider selling activity from the CFO and a director was reported in December, while institutional investors like Vanguard and Durable Capital Partners LP increased their stakes.
RBC Capital Reinstates Coverage of PRVA with "Outperform" Rating
RBC Capital has reinstated its "Outperform" rating on Privia Health Gr (PRVA) with a price target of $31.00 USD, indicating positive sentiment for the company's future. This follows several other analysts in recent months providing "Overweight" or "Buy" ratings and raising price targets. Privia Health Group Inc. is a technology-driven physician-enablement company, and analysts project an average target price of $31.55 with a potential upside of 37.41% from its current price.
Royal Bank Of Canada Initiates Coverage on Privia Health Group (NASDAQ:PRVA)
Royal Bank of Canada has initiated coverage on Privia Health Group (NASDAQ:PRVA) with an "outperform" rating and a $31.00 price target, suggesting a potential upside of 33.9%. Other firms have also raised price targets, contributing to a "Moderate Buy" consensus rating among analysts with an average target of $30.50. Despite positive analyst sentiment, insider selling by a director and the CFO occurred in December, and the stock trades with a high P/E of 178.09.
Privia Health stock rating initiated at Outperform by RBC Capital
RBC Capital initiated coverage on Privia Health Group Inc. (NASDAQ: PRVA) with an Outperform rating and a $31.00 price target, viewing it as the optimal investment in physician enablement due to its high-growth potential, technology-healthcare integration, and strong financial health despite a high P/E ratio. The firm anticipates continued growth from network expansion and fee-based collections, especially as the value-based care landscape matures. This positive outlook aligns with recent strong financial results, including a 27% increase in Practice Collections and a 62% rise in adjusted EBITDA, leading other analysts to also raise their price targets and reiterate positive ratings.
Privia Health stock rating initiated at Outperform by RBC Capital by RBC Capital
RBC Capital initiated coverage on Privia Health Group Inc. (NASDAQ:PRVA) with an Outperform rating and a $31.00 price target, viewing it as a strong investment in physician enablement due to its growth potential and strategic positioning in value-based care. The company, which recently acquired an ACO business from Evolent Health, reported significant increases in practice collections and adjusted EBITDA in its third quarter, leading to several analyst firms raising their price targets and reiterating positive ratings.
Privia Health stock rating initiated at Outperform by RBC Capital
RBC Capital initiated coverage on Privia Health Group Inc. (NASDAQ:PRVA) with an Outperform rating and a $31.00 price target. The firm views Privia Health as an optimal investment in physician enablement within the high-growth healthcare technology sector, highlighting the company's strong revenue growth and strategic acquisitions. Despite a high P/E ratio, analysts maintain a strong buy consensus due to anticipated accelerated growth through an expanding physician network and its payor-agnostic model.
Privia Health stock rating initiated at Outperform by RBC Capital
RBC Capital has initiated coverage on Privia Health Group Inc. (NASDAQ:PRVA) with an Outperform rating and a $31.00 price target, seeing significant upside from its current trading price. The firm considers Privia Health an optimal investment in physician enablement, citing its high-growth potential, strong revenue growth, and robust financial health, despite a high P/E ratio. This positive outlook is further supported by recent strong Q3 performance, an acquisition, and several other analysts raising their price targets.
Citizens reiterates Market Outperform rating on Privia Health stock
Citizens has reiterated its Market Outperform rating and $31.00 price target for Privia Health Group Inc (NASDAQ:PRVA), implying a 28% upside. The firm increased its 2026 and 2027 EBITDA estimates due to Privia's acquisition of Evolent's ACO business, with the new estimates being $143 million and $165 million, respectively. This positive outlook is supported by Privia's strong balance sheet and analyst consensus of a Strong Buy rating.
Privia Health Group, Inc. (PRVA) Stock Analysis: Riding A 29.51% Potential Upside Wave
Privia Health Group, Inc. (PRVA) is highlighted as a compelling investment in the healthcare sector, with a potential upside of 29.51% from its current price of $24.14. The article details the company's innovative physician-enablement model, strong revenue growth, and robust cash generation, supported by an overwhelmingly positive analyst consensus. Despite some valuation challenges, Privia Health's strategic positioning and focus on reinvesting earnings for growth make it an attractive opportunity for investors in health information services.
Citizens reiterates Market Outperform rating on Privia Health stock By Investing.com
Citizens has reiterated its Market Outperform rating and a $31.00 price target for Privia Health Group Inc (NASDAQ:PRVA), suggesting a 28% upside. This positive outlook is supported by a broader analyst consensus of "Strong Buy" and revised EBITDA estimates for 2026 and 2027, reflecting the recent acquisition of Evolent’s ACO business. Despite a slight miss on EPS in Q3 2025, analysts maintain a positive outlook due to strong revenue performance and strategic acquisitions.
Citizens reiterates Market Outperform rating on Privia Health stock
Citizens has reaffirmed its "Market Outperform" rating and set a $31.00 price target for Privia Health Group Inc (NASDAQ:PRVA), suggesting a 28% upside. This decision comes after raising 2026 and 2027 EBITDA estimates due to Privia Health's acquisition of Evolent’s ACO business. Other analysts also show a positive outlook, with several firms adjusting their price targets upwards following Privia Health's strong third-quarter revenue performance.
Privia Health Group, Inc.'s (NASDAQ:PRVA) Stock Has Shown A Decent Performance: Have Financials A Role To Play?
Privia Health Group's stock has shown a decent performance, increasing by 2.1% in the past week. This article examines whether the company's financials, specifically its Return on Equity (ROE) and earnings growth, have contributed to this movement. Despite a low ROE of 3.2% compared to an industry average of 15%, Privia Health Group has achieved an exceptional 52% net income growth over the past five years, largely due to reinvesting all its profits back into the business.
The Zacks Analyst Blog Highlights Hims & Hers Health, Biotricity and Privia Health
This article from Zacks Analyst Blog highlights how Hims & Hers Health (HIMS), Biotricity (BTCY), and Privia Health (PRVA) have shown strong performance in the healthcare IT sector in 2025. These companies have leveraged digital transformation, with Hims & Hers focusing on telehealth, Biotricity on remote patient monitoring, and Privia Health on physician-enablement technology, all achieving over 20% growth. The article examines their growth catalysts and risks as the U.S. healthcare IT market continues to expand significantly.
Privia Health Group, Inc. (NASDAQ:PRVA) Given Consensus Rating of "Moderate Buy" by Analysts
Privia Health Group, Inc. (NASDAQ:PRVA) has received a consensus "Moderate Buy" rating from analysts, with an average one-year price target of $30.42. Insider selling recently occurred, as CFO David Mountcastle and Director Matthew Shawn Morris sold shares in December. Despite a high institutional ownership of 94.48% and a market cap of $2.92 billion, the company has a stretched valuation with a P/E ratio of 182.55, and analysts forecast an FY EPS of approximately $0.14.
Privia Health Group Adjusts Valuation Amid Evolving Market Dynamics in Insurance Sector
Privia Health Group, Inc. has seen a shift in its valuation grade, moving from an expensive to a more attractive standing. The company demonstrates a high P/E ratio of 181 but has also achieved significant operating cash flow of USD 91.86 million and net sales of USD 521.15 million in June 2025, contributing to positive financial sentiment. This adjustment reflects evolving market dynamics within the insurance sector.
Riverbridge Partners LLC Has $115.38 Million Position in Privia Health Group, Inc. $PRVA
Riverbridge Partners LLC reduced its stake in Privia Health Group (NASDAQ:PRVA) by 6.3% in Q3, now holding 4,633,867 shares valued at $115.38 million. Insider transactions on December 12th saw Director Matthew Shawn Morris and CFO David Mountcastle sell a combined total of over $930,000 worth of stock. Analysts currently rate PRVA as a "Moderate Buy" with a consensus price target of $30.42.
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Novan (NOVN)
Analysts maintain a bullish outlook on select healthcare stocks, specifically Nuvalent (NUVL) and Privia Health Group (PRVA). Truist Financial and Barclays reaffirmed Buy ratings for Nuvalent, predicting a significant upside. Similarly, Truist Financial reiterated a Buy rating for Privia Health Group, also forecasting a strong upside.
